Journal
SCIENTIFIC REPORTS
Volume 7, Issue -, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/srep45138
Keywords
-
Categories
Funding
- Region Champagne-Ardenne
- Fond Europeen de Developpement Regional (FEDER)
- le contrat de projet Etat Region CPER
- Ligue contre le cancer, Conference de Coordination Inter Regionale du Grand Est (CCIR-GE) [30036506-UMR7369]
- Eiffel Scholarship of Excellence [870731F]
Ask authors/readers for more resources
Lumican is a small leucine-rich proteoglycan that has been shown to contribute in several physiological processes, but also to exert anticancer activity. On the other hand, it has been recently shown that knockdown of the estrogen receptor alpha (ER alpha) in low invasive MCF-7 (ER alpha+) breast cancer cells and the suppression of ER beta in highly aggressive MDA-MB-231 (ER beta+) cells significantly alter the functional properties of breast cancer cells and the gene expression profile of matrix macromolecules related to cancer progression and cell morphology. In this report, we evaluated the effects of lumican in respect to the ERs-associated breast cancer cell behaviour, before and after suppression of ERs, using scanning electron and confocal microscopies, qPCR and functional assays. Our data pinpointed that lumican significantly attenuated cell functional properties, including proliferation, migration and invasion. Furthermore, it modified cell morphology, inducing cell-cell junctions, evoked EMT/ MET reprogramming and suppressed the expression of major matrix effectors (matrix metalloproteinases and EGFR) implicated in breast cancer progression. The effects of lumican were found to be related to the type of breast cancer cells and the ER alpha/beta type. These data support the anticancer activity of lumican and open a new area for the pharmacological targeting of the invasive breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available